Last reviewed · How we verify
NCT03526848
3BNC117 and 10-1074 in ART-treated Individuals
Phase 1 trial testing 3BNC117 in Human Immunodeficiency Virus in 26 participants. Completed in 11 February 2022.
30 September 2021
Quick facts
| Lead sponsor | Rockefeller University |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 26 |
| Start date | 5 June 2018 |
| Primary completion | 30 September 2021 |
| Estimated completion | 11 February 2022 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- 3BNC117 — full drug profile →
- 10-1074
- Analytical treatment interruption
Conditions studied
- Human Immunodeficiency Virus — all drugs for Human Immunodeficiency Virus →
Sponsor
Rockefeller University
Who can join
Adults 18 to 65, any sex, with Human Immunodeficiency Virus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The proposed study is a phase 1, open label, randomized study to evaluate the safety and antiretroviral activity of seven infusions of 3BNC117 and 10-1074, administered intravenously at 30 mg/kg dose level, in human immunodeficiency virus (HIV)-infected individuals on combination antiretroviral therapy (ART) and during an analytical interruption of ART.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Prolonged viral suppression with anti-HIV-1 antibody therapy.
Gaebler C, Nogueira L, Stoffel E, Oliveira TY, et al · · 2022 · cited 182× · PMID 35418681 · DOI 10.1038/s41586-022-04597-1 -
Broadly neutralizing antibodies for the treatment and prevention of HIV infection.
Caskey M. · · 2020 · cited 81× · PMID 31764199 · DOI 10.1097/coh.0000000000000600 -
Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence.
Huang AS, Ramos V, Oliveira TY, Gaebler C, et al · · 2021 · cited 64× · PMID 34636876 · DOI 10.1084/jem.20211427 -
Broadly neutralizing monoclonal antibodies for HIV prevention.
Miner MD, Corey L, Montefiori D. · · 2021 · cited 34× · PMID 34806308 · DOI 10.1002/jia2.25829 -
The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention.
Thavarajah JJ, Hønge BL, Wejse CM. · · 2024 · cited 31× · PMID 38932203 · DOI 10.3390/v16060911 -
Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?
Hsu DC, Mellors JW, Vasan S. · · 2021 · cited 30× · PMID 34322136 · DOI 10.3389/fimmu.2021.710044 -
Impact of Myeloid Reservoirs in HIV Cure Trials.
Mitchell BI, Laws EI, Ndhlovu LC. · · 2019 · cited 28× · PMID 30835045 · DOI 10.1007/s11904-019-00438-5 -
Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage.
Wagh K, Seaman MS. · · 2023 · cited 23× · PMID 37249911 · DOI 10.1097/coh.0000000000000800
Verify or expand the search:
- PubMed search for NCT03526848
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 3BNC117
Trials testing the same drug.
- NCT04819347 — Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection · Phase 2 · unknown
- NCT03041012 — Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART · Phase 2 · completed
- NCT02850016 — Romidepsin Plus 3BNC117 Phase 2a Study · Phase 2 · completed
- NCT02824536 — 3BNC117 and 10-1074 in HIV Uninfected Adults · Phase 1 · completed
- NCT02446847 — 3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption · Phase 2 · completed
Other recruiting trials for Human Immunodeficiency Virus
Currently open trials in the same condition.
- NCT07530198 — HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong · Phase 1 · recruiting
- NCT06819176 — Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretrovir · Phase 1 · recruiting
- NCT06408142 — Universal Test and Connect for HIV Service Delivery in South Africa · recruiting
- NCT07101458 — The Eswatini PRISM Study on Adolescents Living With HIV · NA · recruiting
- NCT06554223 — The SUSTAIN 2 Study - SUStained HIV Treatment for Adherence After Interruption in Care · NA · recruiting
Other Rockefeller University trials
Trials by the same sponsor.
- NCT06887543 — The Impact of Time Restricted Eating on Type 2 Diabetes · NA · terminated
- NCT06424132 — Thermogenic Silencer Regulatory Factors in Humans · NA · active not recruiting
- NCT06223035 — Myokine Identification Following Acute Exercise · NA · completed
- NCT06146218 — Compassion-Based Resiliency Training (CBRT) Intervention on Racism-based Stress · NA · completed
- NCT05856890 — HepB mAb19 in Individuals With Chronic Hepatitis B Infection · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03526848 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rockefeller University
- Last refreshed: 1 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03526848.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing